How much revenue did MDxHealth generate this year?
MDxHealth has achieved a revenue of 83.28 M USD this year.
MDxHealth Revenue 2024
MDxHealth Revenue
83.28 M USD
Ticker
MDXH.BR
ISIN
BE0003844611
WKN
A0J3N3
In 2024, MDxHealth's sales reached 83.28 M USD, a 17.72% difference from the 70.75 M USD sales recorded in the previous year.
The MDxHealth Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2027e | 129.96 | 14,75 |
| 2026e | 113.21 | 16,93 |
| 2025e | 112.2 | 17,09 |
| 2024e | 83.28 | 23,02 |
| 2023e | 70.75 | 27,10 |
| 2022 | 37.05 | 51,74 |
| 2021 | 22.24 | 46,81 |
| 2020 | 18.46 | 43,01 |
| 2019 | 11.79 | -1,19 |
| 2018 | 28.4 | 57,89 |
| 2017 | 40.51 | 73,54 |
| 2016 | 29.97 | 61,13 |
| 2015 | 17.64 | 53,06 |
| 2014 | 11.67 | 44,73 |
| 2013 | 7.55 | 23,31 |
| 2012 | 5.91 | 80,37 |
| 2011 | 3.74 | 90,11 |
| 2010 | 3.36 | 85,42 |
| 2009 | 3.54 | 92,94 |
| 2008 | 4.42 | 92,08 |
| 2007 | 3.62 | 82,87 |
| 2006 | 3.48 | 97,99 |
| 2005 | 3.83 | 96,34 |
| 2004 | 0.48 | 97,92 |
| 2003 | - | - |
MDxHealth Revenue, EBIT, Net Income BE0003844611 · A0J3N3
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into MDxHealth, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MDxHealth from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MDxHealth’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of MDxHealth. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into MDxHealth’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing MDxHealth’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MDxHealth’s growth potential.
MDxHealth Revenue, EBIT and net profit per share
| Date | MDxHealth Revenue | MDxHealth EBIT | MDxHealth Net Income |
|---|---|---|---|
| 2027e | 129.96 M undefined | 18.07 M undefined | 16.62 M undefined |
| 2026e | 113.21 M undefined | 3.96 M undefined | 2.67 M undefined |
| 2025e | 112.2 M undefined | -10.78 M undefined | -9.19 M undefined |
| 2024e | 83.28 M undefined | -20.91 M undefined | -141.4 M undefined |
| 2023e | 70.75 M undefined | -27.38 M undefined | -180.64 M undefined |
| 2022 | 37.05 M undefined | -37.86 M undefined | -44.04 M undefined |
| 2021 | 22.24 M undefined | -26.84 M undefined | -29 M undefined |
| 2020 | 18.46 M undefined | -26.85 M undefined | -28.66 M undefined |
| 2019 | 11.79 M undefined | -36.88 M undefined | -43.1 M undefined |
| 2018 | 28.4 M undefined | -32.1 M undefined | -32.45 M undefined |
| 2017 | 40.51 M undefined | -12.27 M undefined | -12.29 M undefined |
| 2016 | 29.97 M undefined | -12.85 M undefined | -13.17 M undefined |
| 2015 | 17.64 M undefined | -14.38 M undefined | -14.47 M undefined |
| 2014 | 11.67 M undefined | -15.34 M undefined | -15.26 M undefined |
| 2013 | 7.55 M undefined | -16.07 M undefined | -16.18 M undefined |
| 2012 | 5.91 M undefined | -11.44 M undefined | -11.53 M undefined |
| 2011 | 3.74 M undefined | -9.88 M undefined | -9.67 M undefined |
| 2010 | 3.36 M undefined | -11.08 M undefined | -10.93 M undefined |
| 2009 | 3.54 M undefined | -20.49 M undefined | -19.89 M undefined |
| 2008 | 4.42 M undefined | -16.57 M undefined | -14.91 M undefined |
| 2007 | 3.62 M undefined | -15.02 M undefined | -13.66 M undefined |
| 2006 | 3.48 M undefined | -9.84 M undefined | -9.25 M undefined |
| 2005 | 3.83 M undefined | -5.39 M undefined | -5.32 M undefined |
| 2004 | 480,000 undefined | -6.52 M undefined | -6.45 M undefined |
| 2003 | 0 undefined | -4.52 M undefined | -4.58 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2003 | 0 USD | -4.52 M USD | -4.58 M USD |
| 2004 | 480,000 USD | -6.52 M USD | -6.45 M USD |
| 2005 | 3.83 M USD | -5.39 M USD | -5.32 M USD |
| 2006 | 3.48 M USD | -9.84 M USD | -9.25 M USD |
| 2007 | 3.62 M USD | -15.02 M USD | -13.66 M USD |
| 2008 | 4.42 M USD | -16.57 M USD | -14.91 M USD |
| 2009 | 3.54 M USD | -20.49 M USD | -19.89 M USD |
| 2010 | 3.36 M USD | -11.08 M USD | -10.93 M USD |
| 2011 | 3.74 M USD | -9.88 M USD | -9.67 M USD |
| 2012 | 5.91 M USD | -11.44 M USD | -11.53 M USD |
| 2013 | 7.55 M USD | -16.07 M USD | -16.18 M USD |
| 2014 | 11.67 M USD | -15.34 M USD | -15.26 M USD |
| 2015 | 17.64 M USD | -14.38 M USD | -14.47 M USD |
| 2016 | 29.97 M USD | -12.85 M USD | -13.17 M USD |
| 2017 | 40.51 M USD | -12.27 M USD | -12.29 M USD |
| 2018 | 28.4 M USD | -32.1 M USD | -32.45 M USD |
| 2019 | 11.79 M USD | -36.88 M USD | -43.1 M USD |
| 2020 | 18.46 M USD | -26.85 M USD | -28.66 M USD |
| 2021 | 22.24 M USD | -26.84 M USD | -29 M USD |
| 2022 | 37.05 M USD | -37.86 M USD | -44.04 M USD |
| 2023e | 70.75 M USD | -27.38 M USD | -180.64 M USD |
| 2024e | 83.28 M USD | -20.91 M USD | -141.4 M USD |
| 2025e | 112.2 M USD | -10.78 M USD | -9.19 M USD |
| 2026e | 113.21 M USD | 3.96 M USD | 2.67 M USD |
| 2027e | 129.96 M USD | 18.07 M USD | 16.62 M USD |
MDxHealth stock margins BE0003844611 · A0J3N3
The MDxHealth margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MDxHealth. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MDxHealth.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the MDxHealth's sales revenue. A higher gross margin percentage indicates that the MDxHealth retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the MDxHealth's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the MDxHealth's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MDxHealth's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MDxHealth. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MDxHealth's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
MDxHealth Margin History
| MDxHealth Gross margin | MDxHealth Profit margin | MDxHealth EBIT margin | MDxHealth Profit margin |
|---|---|---|---|
| 2027e | 51.74 % | 13.91 % | 12.79 % |
| 2026e | 51.74 % | 3.5 % | 2.36 % |
| 2025e | 51.74 % | -9.61 % | -8.19 % |
| 2024e | 51.74 % | -25.11 % | -169.78 % |
| 2023e | 51.74 % | -38.71 % | -255.34 % |
| 2022 | 51.74 % | -102.19 % | -118.87 % |
| 2021 | 46.81 % | -120.68 % | -130.4 % |
| 2020 | 43.01 % | -145.45 % | -155.25 % |
| 2019 | -1.19 % | -312.81 % | -365.56 % |
| 2018 | 57.89 % | -113.03 % | -114.26 % |
| 2017 | 73.54 % | -30.29 % | -30.34 % |
| 2016 | 61.13 % | -42.88 % | -43.94 % |
| 2015 | 53.06 % | -81.52 % | -82.03 % |
| 2014 | 44.73 % | -131.45 % | -130.76 % |
| 2013 | 23.31 % | -212.85 % | -214.3 % |
| 2012 | 80.37 % | -193.57 % | -195.09 % |
| 2011 | 90.11 % | -264.17 % | -258.56 % |
| 2010 | 85.42 % | -329.76 % | -325.3 % |
| 2009 | 92.94 % | -578.81 % | -561.86 % |
| 2008 | 92.08 % | -374.89 % | -337.33 % |
| 2007 | 82.87 % | -414.92 % | -377.35 % |
| 2006 | 97.99 % | -282.76 % | -265.8 % |
| 2005 | 96.34 % | -140.73 % | -138.9 % |
| 2004 | 97.92 % | -1,358.33 % | -1,343.75 % |
| 2003 | 51.74 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2003 | 51.74 % | 0 % | 0 % |
| 2004 | 97.92 % | -1,358.33 % | -1,343.75 % |
| 2005 | 96.34 % | -140.73 % | -138.9 % |
| 2006 | 97.99 % | -282.76 % | -265.8 % |
| 2007 | 82.87 % | -414.92 % | -377.35 % |
| 2008 | 92.08 % | -374.89 % | -337.33 % |
| 2009 | 92.94 % | -578.81 % | -561.86 % |
| 2010 | 85.42 % | -329.76 % | -325.3 % |
| 2011 | 90.11 % | -264.17 % | -258.56 % |
| 2012 | 80.37 % | -193.57 % | -195.09 % |
| 2013 | 23.31 % | -212.85 % | -214.3 % |
| 2014 | 44.73 % | -131.45 % | -130.76 % |
| 2015 | 53.06 % | -81.52 % | -82.03 % |
| 2016 | 61.13 % | -42.88 % | -43.94 % |
| 2017 | 73.54 % | -30.29 % | -30.34 % |
| 2018 | 57.89 % | -113.03 % | -114.26 % |
| 2019 | -1.19 % | -312.81 % | -365.56 % |
| 2020 | 43.01 % | -145.45 % | -155.25 % |
| 2021 | 46.81 % | -120.68 % | -130.4 % |
| 2022 | 51.74 % | -102.19 % | -118.87 % |
| 2023e | 51.74 % | -38.71 % | -255.34 % |
| 2024e | 51.74 % | -25.11 % | -169.78 % |
| 2025e | 51.74 % | -9.61 % | -8.19 % |
| 2026e | 51.74 % | 3.5 % | 2.36 % |
| 2027e | 51.74 % | 13.91 % | 12.79 % |
MDxHealth Aktienanalyse
What does MDxHealth do?
MDxHealth SA was founded in 2003 and is a publicly traded company based in Belgium, specializing in the development and marketing of molecular diagnostic tests for cancer diagnosis. The company focuses on developing tests for the diagnosis of prostate, bladder, and kidney cancer, as well as tests for monitoring the progression of these cancer types. The business model of MDxHealth is to develop state-of-the-art molecular diagnostics for cancer medicine and make them accessible to medical professionals and pathologists. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth also provides support to its customers in interpreting test results and choosing the best treatment options for patients. The company has different divisions tailored to the specific needs of patients, doctors, and pathologists. The main divisions are the oncology division and the urology division. In the oncology division, MDxHealth offers various tests for prostate cancer, including the Prognostic Oncotype DX Test used for predicting the progression of prostate cancer. The urology division of MDxHealth focuses on developing tests for bladder cancer and kidney cancer. The key tests in this division include the ConfirmMDx Test used for diagnosing bladder cancer, and the SelectMDx Test used for diagnosing aggressive prostate cancer. MDxHealth also has a significant presence in genomics and personalized medicine. The company partners with the University of Miami Miller School of Medicine to research and improve the application of genetic tests in cancer diagnosis and treatment. MDxHealth also collaborates closely with other leading research institutions and cancer centers to drive innovation in molecular diagnostics. Overall, MDxHealth offers a wide range of molecular diagnostic tests for cancer diagnosis and monitoring. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth is a key player in the field of molecular diagnostics and has the potential to improve the lives of cancer patients worldwide. MDxHealth ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding MDxHealth's Sales Figures
The sales figures of MDxHealth originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing MDxHealth’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize MDxHealth's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in MDxHealth’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about MDxHealth stock
How much was the turnover of the company MDxHealth compared to the previous year?
The revenue of MDxHealth has increased by 17.72% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of MDxHealth?
The revenue of MDxHealth is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of MDxHealth measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of MDxHealth so important for investors?
The revenue of MDxHealth is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does MDxHealth pay?
Over the past 12 months, MDxHealth paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MDxHealth is expected to pay a dividend of 0 USD.
What is the dividend yield of MDxHealth?
The current dividend yield of MDxHealth is .
When does MDxHealth pay dividends?
MDxHealth pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MDxHealth?
MDxHealth paid dividends every year for the past 0 years.
What is the dividend of MDxHealth?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MDxHealth located?
MDxHealth is assigned to the 'Health' sector.
Wann musste ich die Aktien von MDxHealth kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MDxHealth from 7/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/29/2024.
When did MDxHealth pay the last dividend?
The last dividend was paid out on 7/29/2024.
What was the dividend of MDxHealth in the year 2023?
In the year 2023, MDxHealth distributed 0 USD as dividends.
In which currency does MDxHealth pay out the dividend?
The dividends of MDxHealth are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von MDxHealth
Our stock analysis for MDxHealth Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MDxHealth Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
